Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 63.

van Bergen, J M G; Li, X; Hua, J; Schreiner, S J; Steininger, S C; Quevenco, F C; Wyss, M; Gietl, A F; Treyer, V; Leh, S E; Buck, F; Nitsch, R M; Pruessmann, K P; van Zijl, P C M; Hock, C; Unschuld, P G (2016). Colocalization of cerebral iron with amyloid beta in mild cognitive impairment. Scientific Reports, 6:35514.

Riese, F; Gietl, A; Zölch, N; Henning, A; O’Gorman, R; Kälin, A M; Leh, S E; Buck, A; Warnock, G; Edden, R A E; Luechinger, R; Hock, C; Kollias, S; Michels, Lars (2015). Posterior cingulate GABA and glutamate+glutamine are reduced in amnestic mild cognitive impairment and are unrelated to amyloid deposition and APOE genotype. Neurobiology of Aging, 36(1):53-59.

Michels, Lars; Riese, F; Gietl, A; Hock, C; Kollias, S (2014). Altered functional connectivity and global network properties in amnestic mild cognitive impairment. Alzheimer's & Dementia, 10(4):P826.

Santuccione, A C; Merlini, M; Shetty, A; Tackenberg, C; Bali, J; Ferretti, M T; McAfoose, J; Kulic, L; Bernreuther, C; Welt, T; Grimm, J; Glatzel, M; Rajendran, L; Hock, C; Nitsch, R M (2013). Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice. Molecular Psychiatry, 18(3):358-368.

Spescha, R D; Shi, Y; Wegener, S; Keller, S; Weber, B; Wyss, M M; Lauinger, N; Tabatabai, G; Paneni, F; Cosentino, F; Hock, C; Weller, M; Nitsch, R M; Lüscher, T F; Camici, G G (2013). Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. European Heart Journal, 34(2):96-103.

Kulic, L; McAfoose, J; Welt, T; Tackenberg, C; Späni, C; Wirth, F; Finder, V; Konietzko, U; Giese, M; Eckert, A; Noriaki, K; Shimizu, T; Murakami, K; Irie, K; Rasool, S; Glabe, C; Hock, C; Nitsch, R M (2012). Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation. Translational Psychiatry, 2:e183.

Schipke, C G; Peters, O; Heuser, I; Grimmer, T; Sabbagh, M N; Sabri, O; Hock, C; Kunz, M; Kuhlmann, J; Reininger, C; Blankenburg, M (2012). Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 33(6):416-422.

Marques-Vidal, P; Bochud, M; Bastardot, F; Lüscher, T; Ferrero, F; Gaspoz, J M; Paccaud, F; Urwyler, A; von Känel, R; Hock, C; Waeber, G; Preisig, M; Vollenweider, P (2011). Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (CoLaus study). PLoS ONE, 6(6):e21002.

Brodaty, H; Breteler, M M B; Dekosky, S T; Dorenlot, P; Fratiglioni, L; Hock, C; Kenigsberg, P A; Scheltens, P; De Strooper, B (2011). The world of dementia beyond 2020. Journal of the American Geriatrics Society, 59(5):923-927.

Serrano-Pozo, A; William, C M; Ferrer, I; Uro-Coste, E; Delisle, M B; Maurage, C A; Hock, C; Nitsch, R M; Masliah, E; Growdon, J H; Frosch, M P; Hyman, B T (2010). Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain: A Journal of Neurology, 133(5):1312-1327.

Alzheimerdemenz: Status quo der Immuntherapie. Edited by: Hock, C (2009). Leading Options: Neurologie & Psychiatrie: Universimed.

Biscaro, B; Lindvall, O; Hock, C; Ekdahl, C T; Nitsch, R M (2009). Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. Journal of Neuroscience, 29(45):14108-14119.

Burns, A; Bernabei, R; Bullock, R; Jentoft, A J C; Frölich, L; Hock, C; Raivio, M; Triau, E; Vandewoude, M; Wimo, A; Came, E; Van Baelen, B; Hammond, G L; van Oene, J C; Schwalen, S (2009). Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurology, 8(1):39-47.

Miele, G; Seeger, H; Marino, D; Eberhard, R; Heikenwalder, M; Stoeck, K; Basagni, M; Knight, R; Green, A; Chianini, F; Wüthrich, R P; Hock, C; Zerr, I; Aguzzi, A (2008). Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS ONE, 3(12):e3870.

Treyer, V; Streffer, J; Ametamey, S M; Bettio, A; Bläuenstein, P; Schmidt, M; Gasparini, F; Fischer, U; Hock, C; Buck, A (2008). Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 35(4):766-770.

Nitsch, R M; Hock, C (2008). Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Neurotherapeutics, 5(3):415-420.

Wollmer, M A; Sleegers, K; Ingelsson, M; Zekanowski, C; Brouwers, N; Maruszak, A; Brunner, F; Huynh, K D; Kilander, L; Brundin, R M; Hedlund, M; Giedraitis, V; Glaser, A; Engelborghs, S; De Deyn, P P; Kapaki, E; Tsolaki, M; Daniilidou, M; Molyva, D; Paraskevas, G P; Thal, D R; Barcikowska, M; Kuznicki, J; Lannfelt, L; Van Broeckhoven, C; Nitsch, R M; Hock, C; Papassotiropoulos, A (2007). Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics, 8(3):179-188.

Mondadori, C R A; de Quervain, D J F; Buchmann, A; Mustovic, H; Wollmer, M A; Schmidt, C F; Boesiger, P; Hock, C; Nitsch, R M; Papassotiropoulos, A; Henke, K (2007). Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cerebral Cortex, 17(8):1934-1947.

De Ferrari, G V; Papassotiropoulos, A; Biechele, T; Wavrant-De Vrieze, F; Avila, M E; Major, M B; Myers, A; Sáez, K; Henríquez, J P; Zhao, A; Wollmer, M A; Nitsch, R M; Hock, C; Morris, C M; Hardy, J; Moon, R T (2007). Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 104(22):9434-3439.

Treyer, V; Streffer, J; Wyss, M T; Bettio, A; Ametamey, S M; Fischer, U; Schmidt, M; Gasparini, F; Hock, C; Buck, A (2007). Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. Journal of Nuclear Medicine, 48(7):1207-1215.

Mondadori, C R A; Buchmann, A; Mustovic, H; Schmidt, C F; Boesiger, P; Nitsch, R M; Hock, C; Streffer, J; Henke, K (2006). Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years. Brain: A Journal of Neurology, 129(Pt 11):2908-2922.

Wollmer, M A; Kapaki, E; Hersberger, M; Muntwyler, J; Brunner, F; Tsolaki, M; Akatsu, H; Kosaka, K; Michikawa, M; Molyva, D; Paraskevas, G P; Lütjohann, D; von Eckardstein, A; Hock, C; Nitsch, R M; Papassotiropoulos, A (2006). Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease. American Journal of Medical Genetics. Part B, 141B(5):534-536.

Wollmer, M A; Nitsch, R M; Hock, C; Papassotiropoulos, A (2006). Genetic association study on colony-stimulating factor 1 in Alzheimer's disease. Neurodegenerative Diseases, 3(6):334-337.

Papassotiropoulos, A; Wollmer, M A; Tsolaki, M; Brunner, F; Molyva, D; Lütjohann, D; Nitsch, R M; Hock, C (2005). A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. Journal of Clinical Psychiatry, 66(7):940-947.

Papassotiropoulos, A; Henke, K; Aerni, A; Coluccia, D; Garcia, E; Wollmer, M A; Huynh, K D; Monsch, A U; Stähelin, H B; Hock, C; Nitsch, R M; de Quervain, D J F (2005). Age-dependent effects of the 5-hydroxytryptamine-2a-receptor polymorphism (His452Tyr) on human memory. NeuroReport, 16(8):839-842.

Papassotiropoulos, A; Lambert, J C; Wavrant-De Vrièze, F; Wollmer, M A; von der Kammer, H; Streffer, J R; Maddalena, A; Huynh, K D; Wolleb, S; Lütjohann, D; Schneider, B; Thal, D R; Grimaldi, L M E; Tsolaki, M; Kapaki, E; Ravid, R; Konietzko, U; Hegi, T; Pasch, T; Jung, H; Braak, H; Amouyel, P; Rogaev, E I; Hardy, J; Hock, C; Nitsch, R M (2005). Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neurodegenerative Diseases, 2(5):233-241.

Hock, C; Nitsch, R M (2005). Clinical observations with AN-1792 using TAPIR analyses. Neurodegenerative Diseases, 2(5):273-276.

Wiltfang, J; Lewczuk, P; Riederer, P; Grünblatt, E; Hock, C; Scheltens, P; Hampel, H; Vanderstichele, H; Iqbal, K; Galasko, D; Lannfelt, L; Otto, M; Esselmann, H; Henkel, A W; Kornhuber, J; Blennow, K (2005). Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World Journal of Biological Psychiatry, 6(2):69-84.

Bosshardt, S; Schmidt, C F; Jaermann, T; Degonda, N; Boesiger, P; Nitsch, R M; Hock, C; Henke, K (2005). Effects of memory consolidation on human hippocampal activity during retrieval. Cortex, 41(4):486-498.

Koller, M F; Papassotiropoulos, A; Henke, K; Behrends, B; Noda, S; Kratzer, A; Hock, C; Hofmann, M (2005). Evidence of a genetic basis of Morgagni-Stewart-Morel syndrome. A case report of identical twins. Neurodegenerative Diseases, 2(2):56-60.

Degonda, N; Mondadori, C R A; Bosshardt, S; Schmidt, C F; Boesiger, P; Nitsch, R M; Hock, C; Henke, K (2005). Implicit associative learning engages the hippocampus and interacts with explicit associative learning. Neuron, 46(3):505-520.

Papassotiropoulos, A; Tsolaki, M; Wollmer, M A; Molyva, D; Thal, D R; Huynh, K D; Tracy, J; Staehelin, H B; Monsch, A U; Nitsch, R M; Hock, C (2005). No association of a non-synonymous PLAU polymorphism with Alzheimer's disease and disease-related traits. American Journal of Medical Genetics. Part B, 132B(1):21-23.

Bosshardt, S; Degonda, N; Schmidt, C F; Boesiger, P; Nitsch, R M; Hock, C; Henke, K (2005). One month of human memory consolidation enhances retrieval-related hippocampal activity. Hippocampus, 15(8):1026-1040.

Hock, C; Nitsch, R M (2005). Stand der Forschung zu innovativen Therapieverfahren der Alzheimer-Demenz. In: Berger, M; Normann, C. Highlights der Psychiatrie und Psychotherapie 2005⁄06. München: Urban & Fischer, 3-10.

Papassotiropoulos, A; Maddalena, A; Gretener, D; Nitsch, R M; Hock, C (2004). Cerebrospinal fluid biomarkers for the diagnosis of Alzheimer's disease. In: Hyman, B T; Demonet, L F; Christen, Y. The Living Brain and Alzheimer’s Disease. Berlin [etc.]: Springer Verlag , 17-24.

Maddalena, A S; Papassotiropoulos, A; Gonzalez-Agosti, C; Signorell, A; Hegi, T; Pasch, T; Nitsch, R M; Hock, C (2004). Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegenerative Diseases, 1(4-5):231-235.

Finckh, U; Hock, C; Nitsch, R M (2004). Die Alzheimer-Krankheit: Molekulare Grundlagen und Therapieansätzte. In: Ganten, D; Ruckpaul, K; Ruiz-Torres, A. Molekularmedizinische Grundlagen von altersspezifischen Erkrankungen. Heidelberg: Springer Verlag, 148-179.

Maddalena, A S; Fox, M; Hofmann, M; Hock, C (2004). Esophageal dysfunction on psychotropic medication. A case report and literature review. Pharmacopsychiatry, 37(3):134-138.

Alberici, A; Gobbo, C; Panzacchi, A; Nicosia, F; Ghidoni, R; Benussi, L; Hock, C; Papassotiropoulos, A; Liberini, P; Growdon, J H; Frisoni, G B; Villa, A; Zanetti, O; Cappa, S; Fazio, F; Binetti, G (2004). Frontotemporal dementia: impact of P301L tau mutation on a healthy carrier. Journal of Neurology, Neurosurgery, and Psychiatry, 75(11):1607-1610.

de Quervain, D J F; Poirier, R; Wollmer, M A; Grimaldi, L M E; Tsolaki, M; Streffer, J R; Hock, C; Nitsch, R M; Mohajeri, M H; Papassotiropoulos, A (2004). Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Human Molecular Genetics, 13(1):47-52.

Aerni, A; Traber, R; Hock, C; Roozendaal, B; Schelling, G; Papassotiropoulos, A; Nitsch, R M; Schnyder, U; de Quervain, D J F (2004). Low-dose cortisol for symptoms of posttraumatic stress disorder. American Journal of Psychiatry, 161(8):1488-1490.

Günther, C; von Hadeln, K; Müller-Thomsen, T; Alberici, A; Binetti, G; Hock, C; Nitsch, R M; Stoppe, G; Reiss, J; Gal, A; Finckh, U (2004). Possible association of mitochondrial transcription factor A (TFAM) genotype with sporadic Alzheimer disease. Neuroscience Letters, 369(3):219-223.

de Quervain, D J F; Henke, K; Aerni, A; Coluccia, D; Wollmer, M A; Hock, C; Nitsch, R M; Papassotiropoulos, A (2003). A functional genetic variation of the 5-HT2a receptor affects human memory. Nature Neuroscience, 6(11):1141-1142.

Wollmer, M A; Streffer, J R; Lütjohann, D; Tsolaki, M; Iakovidou, V; Hegi, T; Pasch, T; Jung, H H; von Bergmann, K; Nitsch, R M; Hock, C; Papassotiropoulos, A (2003). ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiology of Aging, 24(3):421-426.

Hock, C; Konietzko, U; Streffer, J R; Tracy, J; Signorell, A; Müller-Tillmanns, B; Lemke, U; Henke, K; Moritz, E; Garcia, E; Wollmer, M A; Umbricht, D; de Quervain, D J F; Hofmann, M; Maddalena, A; Papassotiropoulos, A; Nitsch, R M (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 38(4):547-554.

Finckh, U; van Hadeln, K; Müller-Thomsen, T; Alberici, A; Binetti, G; Hock, C; Nitsch, R M; Stoppe, G; Reiss, J; Gal, A (2003). Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2. Neurogenetics, 4(4):213-217.

Hock, C (2003). Biochemical aspects of dementias. Dialogues in Clinical Neuroscience, 5(1):27-33.

Maddalena, A; Papassotiropoulos, A; Müller-Tillmanns, B; Jung, H H; Hegi, T; Nitsch, R M; Hock, C (2003). Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Archives of Neurology, 60(9):1202-1206.

Henke, K; Treyer, V; Weber, B; Nitsch, R M; Hock, C; Wieser, H G; Buck, A (2003). Functional neuroimaging predicts individual memory outcome after amygdalohippocampectomy. NeuroReport, 14(9):1197-1202.

Wollmer, M A; Streffer, J R; Tsolaki, M; Grimaldi, L M E; Lütjohann, D; Thal, D; von Bergmann, K; Nitsch, R M; Hock, C; Papassotiropoulos, A (2003). Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Molecular Psychiatry, 8(6):635-638.

Papassotiropoulos, A; Hock, C; Nitsch, R M (2003). Genetik gerontopsychiatrischer Erkrankungen. In: Förstl, H. Lehrbuch der Gerontopsychiatrie und –psychotherapie: Grundlagen, Klinik, Therapie. Stuttgart: Thieme, 27-36.

de Quervain, D J F; Henke, K; Aerni, A; Treyer, V; McGaugh, J L; Berthold, T; Nitsch, R M; Buck, A; Roozendaal, B; Hock, C (2003). Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe. European Journal of Neuroscience, 17(6):1296-1302.

Papassotiropoulos, A; Streffer, J R; Tsolaki, M; Schmid, S; Thal, D; Nicosia, F; Iakovidou, V; Maddalena, A; Lütjohann, D; Ghebremedhin, E; Hegi, T; Pasch, T; Träxler, M; Brühl, A; Benussi, L; Binetti, G; Braak, H; Nitsch, R M; Hock, C (2003). Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Archives of Neurology, 60(1):29-35.

Hofmann, M; Rösler, A; Schwarz, W; Müller-Spahn, F; Kräuchi, K; Hock, C; Seifritz, E (2003). Interactive computer-training as a therapeutic tool in Alzheimer's disease. Comprehensive Psychiatry, 44(3):213-219.

Henke, K; Mondadori, C R A; Treyer, V; Nitsch, R M; Buck, A; Hock, C (2003). Nonconscious formation and reactivation of semantic associations by way of the medial temporal lobe. Neuropsychologia, 41(8):863-876.

Stoermer, R; Drewe, J; Dursteler-Mac Farland, K M; Hock, C; Mueller-Spahn, F; Ladewig, D; Stohler, R; Mager, R (2003). Safety of injectable opioid maintenance treatment for heroin dependence. Biological Psychiatry, 54(8):854-861.

Streffer, J R; Papassotiropoulos, A; Kurosinski, P; Signorell, A; Wollmer, M A; Tsolaki, M; Iakovidou, V; Hörndli, F; Bosset, J; Götz, J; Nitsch, R M; Hock, C (2003). Saitohin gene is not associated with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 74(3):362-363.

Orgogozo, J M; Gilman, S; Dartigues, J F; Laurent, B; Puel, M; Kirby, L C; Jouanny, P; Dubois, B; Eisner, L; Flitman, S; Michel, B F; Boada, M; Frank, A; Hock, C (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 61(1):46-54.

Hock, C; Maddalena, A; Raschig, A; Müller-Spahn, F; Eschweiler, G; Hager, K; Heuser, I; Hampel, H; Müller-Thomsen, T; Oertel, W; Wienrich, M; Signorell, A; Gonzalez-Agosti, C; Nitsch, R M (2003). Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid, 10(1):1-6.

Hock, C; Konietzko, U; Papassotiropoulos, A; Wollmer, A; Streffer, J; von Rotz, R C; Davey, G; Moritz, E; Nitsch, R M (2002). Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nature Medicine, 8(11):1270-1275.

Wollmer, M A; Papassotiropoulos, A; Streffer, J R; Grimaldi, L M E; Kapaki, E; Salani, G; Paraskevas, G P; Maddalena, A; de Quervain, D; Bieber, C; Umbricht, D; Lemke, U; Bosshardt, S; Degonda, N; Henke, K; Hegi, T; Jung, H H; Pasch, T; Hock, C; Nitsch, R M (2002). Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's disease. Psychiatric Genetics, 12(3):155-160.

Hofmann, M; Hock, C (2001). Alzheimer's disease: antidementive drugs. In: Smelser, N J; Baltes, P B. International Encyclopedia of the Social and Behavioral Sciences. Amsterdam: Elsevier, 418-423.

Finckh, U; Müller-Thomsen, T; Mann, U; Eggers, C; Marksteiner, J; Meins, W; Binetti, G; Alberici, A; Sonderegger, P; Hock, C; Nitsch, R M; Gal, A (2000). High frequency of mutations in four different disease genes in early-onset dementia. Annals of the New York Academy of Sciences, 920:100-106.

This list was generated on Thu Oct 19 12:03:26 2017 CEST.